

(Translation)

JAPAN PATENT OFFICE

5 This is to certify that the annexed is a true copy of the following application as filed with this office.

Date of Application: July 1, 2002

10 Application Number: Patent Application No. 2002-192177
[ST.10/C]: [JP2002-192177]

Applicant(s): SANAKA, Tsutomu
SHIMIZU PHARMACEUTICAL CO., LTD.

15

20 September 19, 2003

Yasuo IMAI

Commissioner, Japan Patent Office

25

Patent Application Number 2002-192177

[Name of Document] Application for Patent
[Reference No.] SSK2115
[Addresses] To Commissioner of the Patent Office
[IPC] A61K 9/08
5 A61M 1/14

[Inventor]

[Address] 4-24-7, Hongo, Bunkyo-ku, Tokyo

[Name] SANAHA, Tsutomu

[Inventor]

10 [Address] 3730-2, Imaizumi, Fuji-shi, Shizuoka

[Name] WAKABAYASHI, Maki

[Inventor]

[Address] 15-10, Nakanodai 1-chome, Fujikawa-cho,
Ihara-gun, Shizuoka

15 [Name] SANO, Yukihiro

[Applicant for the Patent]

[Identification No.] 392004048

[Name] SANAHA, Tsutomu

[Applicant for the Patent]

20 [Identification No.] 391030963

[Name] Shimizu Pharmaceutical Co., Ltd.

[Representative] SUZUKI, Yohei

[Applicant for the Patent]

[Identification No.] 500071175

25 [Name] Shimizu Medical Co., Ltd.

[Representative] HIRANO, Mari

Patent Application Number 2002-192177

[Charge]

[Account Number] 035839

[Total Amount] ¥21,000

[List of the Documents]

5 [Item] Specification 1

[Item] Abstract 1

[Proof] requested

【Disclosure of the invention】

【0001】

【Technical field】

The present invention relates to a perfusate preparation
5 for use in peritoneal dialysis, including peritoneal dialysates
for use in continuous ambulatory peritoneal dialysis (CAPD).

【0002】

【Background Art】

Peritoneal dialysate such as a perfusate designed for use
10 in CAPD, is designed to help patients suffering end stage renal
failure to dispose of waste products through the peritoneum and
thereby maintain the normal balance of various components of
the bodily fluid. A typical CAPD perfusate contains
electrolytes such as sodium chloride, calcium chloride, and
15 magnesium chloride, as well as a lactate or a bicarbonate to
serve as an alkalizer. It also contains glucose to serve as
an osmotic agent that acts to keep the perfusate hypertonic,
so that ultrafiltration of the perfusate is ensured.

【0003】

20 Glucose has long been used as an osmotic agent in
perfusates to establish a desired osmotic pressure because it
is readily metabolized in the body, is effective in removing
water, and is inexpensive. However, the potential effects that
a high glucose level has on the body and its metabolism are now
25 an issue of significant concern. For example, the peritoneum
of a patient undergoing peritoneal dialysis is constantly

exposed to the solution with high glucose concentration. Thus, the peritoneum will eventually deteriorate over the course of long-term dialysis and gradually lose its ability to remove water. In some cases, termination of the treatment is the only
5 choice. In addition, a significant amount of glucose passes through the peritoneum into blood, increasing the blood glucose level. This not only makes the controlling of blood glucose level difficult in patients of diabetic nephropathy but also often leads to hyperinsulinemia in those who are non-diabetic.
10 The high blood glucose level may also accompany hyperlipidemia.

【0004】

Although it is desired that peritoneal dialysates have a neutral pH above 6.0 in the proximity of physiological pH, glucose tends to decompose in neutral or weakly basic pH ranges
15 during the production and storage of the dialysates. As a result, the pH of glucose decreases over time, causing coloring of the solution or an increase in the amount of degraded products, such as 5-hydroxymethyl furfural (5-HMF), formic acid, and aldehydes. Not only are these degraded products cytotoxic, but
20 also some reports suggest that they also facilitate the formation of advanced glycosylation end-products (AGE), compounds suspected to be involved in the development of amyloidosis or other complications. For this reason, peritoneal dialysates are typically designed to show a slightly
25 acidic pH. This, however, irritates the peritoneum and facilitates its deterioration.

【0005】

To counteract these problems, one technique uses a container having two separate compartments so that glucose can be stored separately from the components that facilitate the decomposition of glucose, while another approach provides a glucose solution in small volumes but at a high concentration (See, for example, Japanese Patent Laid-Open Publication No. Hei 3-195561, Japanese Patent Laid-Open Publication No. 2000-51348, Japanese National Publication No. Hei 7-500992, and International Patent Publication No. WO99/09953). The approach to use the two-compartment container, however, is rather complicated since it requires mixing of the two formulations by removing a separator or opening a clip. Also, the technique still involves the use of a solution with high glucose concentration, and the problem of the effects of high glucose concentration on the body and its metabolism is left unattended.

【0006】

Also, much effort has been devoted to finding an alternative to glucose that can serve as an ideal osmotic agent. Among the potential alternatives that have been proposed thus far are amino acids and polypeptides, which are described in Japanese Patent No. 3065352 and Japanese Patent Publication No. Hei 7-504351, respectively. One drawback of these approaches is that the blood urea nitrogen (BUN) levels tend to rise. Also, in some cases, only a less volume of water was removed in these

approaches than is possible by the use of glucose. Another type of peritoneal dialysate disclosed in Japanese Patent Nos. 1824784, 2120679, and 2106222 makes use of glucose polymers or the like. Though in small amounts, the absorption of these polymers by the living body and the accumulation of the polymers and the degraded products in the body pose a significant problem.

【0007】

【The problem to be solved in the Invention】

Accordingly, it is an objective of the present invention to eliminate the problems of the conventional techniques by providing a stable neutral peritoneal dialysate that contains a substance other than glucose to serve as an osmotic agent.

【0008】

【Means to solve the problem】

In an effort to find a solution to the aforementioned problems, the present inventors have made a finding that, by using a taurine compound as an alternative to glucose to serve as an osmotic agent, a stable neutral peritoneal dialysate can be provided. This finding ultimately led the present inventors to complete the present invention. As used herein, the term "taurine compound" includes, aside from taurine itself, any precursor of taurine, such as hypotaurine and thiotaurine.

Taurine, also known as 2-aminoethanesulfonic acid, acts as an osmotic agent that helps cells maintain a desired osmotic balance against hypertonic extracellular conditions created by

urea and electrolytes during the urine concentration in kidneys. Taurine is abundant in the body and is synthesized *in vivo* from methionine via cysteine. There have been some reports suggesting that the synthesis of taurine is inhibited in patients undergoing CAPD and taurine levels in plasma and muscles in these patients remain low.

This implies that a solution containing a taurine compound can serve as an effective peritoneal dialysate that has minimum effects on the body and its metabolism.

10 【0009】

Accordingly the present invention provides:

(1) a peritoneal dialysate containing a taurine compound along with an electrolyte and an alkalizer;

15 (2) The peritoneal dialysate according to (1), wherein the alkalizer is a lactate, a citrate, or a bicarbonate, and the electrolyte is sodium ion, calcium ion, magnesium ion, or chloride ion;

(3) The peritoneal dialysate according to claims 1 or 2, having an osmotic pressure of 300 to 680 mOsm;

20 (4) The peritoneal dialysate according to any one of claims 1 to 3, wherein the pH upon use is adjusted to a value of 6.0 to 7.5;

(5) The peritoneal dialysate according to any one of claims 1 to 4, provided in a one-compartment container;

25 (6) The peritoneal dialysate according to any one of claims 1 to 4, provided in a one-compartment container; and

(7) A peritoneal dialysate, containing 1 to 5 w/v% of taurine, 25 to 45 mEq/L of sodium lactate, 110 to 150 mEq/L of sodium ion, 0.5 to 5 mEq/L of calcium ion, 0.1 to 2.0 mEq/L of magnesium ion, and 80 to 110 mEq/L of chloride ion and having a pH of 6.0 to 7.5.

【0010】

【Best Mode For Implementing The Invention】

One characteristic of the present invention resides in that a taurine compound is added to a peritoneal dialysate to serve as an osmotic agent. Taurine, an amphoteric ion, exhibit a neutral pH when dissolved in water and has the ability to buffer pH changes. For this reason, taurine can be used to stabilize the pH of peritoneal dialysates during sterilization and storage. Furthermore, taurine is more stable against the sterilization process than glucose, which is advantageous since, through the use of taurine, a neutral peritoneal dialysate can be formulated as a single solution that can be stored in a single compartment container. The present invention also takes advantage of physiological activities of taurine for the purposes of improving functions of livers and circulatory systems, improving lipid metabolism, and facilitating diuresis.

【0011】

Preferably, the amount of taurine compound to serve as an osmotic agent is from 1 to 5 w/v%. The peritoneal dialysate is preferably adjusted to have an osmotic pressure of 300 to

680 mOsm and more preferably 300 to 500 mOsm, while the osmotic pressure may vary depending on the amount of ions of electrolytes in the peritoneal dialysate.

According to the present invention, a taurine compound
5 may be added to the peritoneal dialysate along with glucose. When taurine is present in the dialysate together with glucose, the ability of taurine to serve as a buffer helps maintain the pH of the dialysate at a neutral value. To this end, the amount of taurine is preferably from 0.01 to 5 w/v%.

10 [0012]

An alkalizer for use in the present invention may be a lactate, a citrate, or a hydrogencarbonate. An electrolyte for use in the present invention includes sodium ion, calcium ion, magnesium ion, or chloride ion, each of which
15 is commonly in use in peritoneal dialysis. The electrolytes are preferably used in the form of sodium chloride, calcium chloride, and magnesium chloride. Aside from the components above, the peritoneal dialysate of the present invention may further contain various amino acids, trace elements, and other
20 components commonly in use in peritoneal dialysates.

[0013]

The peritoneal dialysate of the present invention preferably contains each of the above-described components in the following concentration ranges:

25	sodium ion	110 to 150 mEq/L
	calcium ion	0.5 to 5 mEq/L

	magnesium ion	0.1 to 2.0 mEq/L
	chloride ion	80 to 110 mEq/L
	alkalizer	25 to 45 mEq/L
	glucose	0 to 4 w/v%
5	taurine compound	0.01 to 5 w/v%

【0014】

Preferably, the peritoneal dialysate has a pH of 6.0 to 7.5. A pH conditioner for use in the peritoneal dialysate may be any commonly used pH conditioner, including sodium hydroxide, sodium hydrogencarbonate, hydrochloric acid, lactic acid, and citric acid.

【0015】

According to the present invention, the addition of taurine compound as an alternative to glucose to serve as an osmotic agent permits formulation of a stable peritoneal dialysate as a single solution, although, if necessary, the dialysate may be provided in the form of two or more separate solutions.

The peritoneal dialysate is generally provided in a plastic container made of such materials as polyethylene, polypropylene, polyvinyl chloride, polyester, ethylene/vinyl acetate copolymer, nylon, or composite materials thereof. This container preferably includes a single compartment for holding the dialysate while it may include two or more compartments if desired.

While the peritoneal dialysate can be sterilized by

common heating process, it may also be sterilized in a proper manner by a sterile filtration process.

【0016】

When necessary, containers of the peritoneal dialysate
5 may be packaged by gas barrier material or the dialysate may be placed in plastic containers having the same property. The gas barrier property is a property of a material that permits little or no penetration of gases such as oxygen, nitrogen, carbon dioxide, and water vapor. Examples of the plastic
10 material having the gas barrier property includes ethylene/vinyl alcohol copolymer, polyvinylidene chloride, nylon with gas barrier property, plastic materials coated or laminated with these resins, or plastic materials coated with a thin film of aluminum, aluminum oxide, silicon oxide or other
15 proper materials. This plastic material may or may not be transparent.

When it is desired to package the container of the peritoneal dialysate by the gas barrier material, the space between the container and the material may be filled with
20 gaseous nitrogen, carbon dioxide or other inert gases, which may be used independently or as a proper mixture. Alternatively, the container of the peritoneal dialysate may be packaged with the gas barrier material while air is removed.

【0017】

25 **【Examples】**

The present invention will now be described with reference to

Examples.

【0018】

(Example 1) 107.6g of sodium chloride, 5.14g of calcium chloride dihydrate, 1.016g of magnesium chloride hexahydrate, 179.2g of 50% sodium lactate solution, and 200g of taurine were dissolved in a proper amount of water for injection. Sodium hydroxide was then added to adjust the pH of the solution to 7 and to give a final volume of 20L. This solution was designated as a Test Solution 1. Similarly, three solutions, having the same composition as Test Solution 1 but containing 360g and 560g of taurine, respectively, were prepared and were designated as Test Solutions 2 and 3, respectively. A solution containing 300g of glucose in place of taurine was designated as a Comparative Solution. 1500mL of each solution was placed in a polypropylene bag and was sterilized in an autoclave.

Each solution was observed before and after the sterilization and after being stored for 2 weeks at 60° C at 30%RH and was examined for any changes. The results are shown in Table 1 below.

【0019】

【Table 1】

Sample	Examined properties	Before sterilization	After sterilization	2 weeks later
Test Sltn 1	Appearance	Clear and colorless	Clear and colorless	Clear and colorless
	pH	7.34	7.36	7.34
	O.P. (mOsm)	324	325	324
	Taurine (w/v%)	0.97	0.97	0.96
Test Sltn 2	Appearance	Clear and colorless	Clear and colorless	Clear and colorless
	pH	7.30	7.31	7.30
	O.P. (mOsm)	386	386	385
	Taurine (w/v%)	1.76	1.79	1.79
Test Sltn 3	Appearance	Clear and colorless	Clear and colorless	Clear and colorless
	pH	7.29	7.29	7.29
	O.P. (mOsm)	466	467	466
	Taurine (w/v%)	2.76	2.76	2.75
Comp. Sltn	Appearance	Clear and colorless	Clear and colorless	Clear and faint yellow
	pH	7.13	6.18	5.85
	O.P. (mOsm)	337	338	338
	Glucose (w/v%)	1.49	1.41	1.41

O.P. = osmotic pressure

【0020】

As shown in Table 1 above, no significant change was

observed in the appearance, pH, osmotic pressure, or the taurine content in any of Test Solutions 1, 2 and 3 after autoclaving and after the 2-week storage period at 60°C, proving the stability of each Test Solution. In comparison, the pH of Comparative Solution was significantly decreased after autoclaving, as was its glucose content. After the 2-week storage period, Comparative Solution was colored and its pH was significantly changed. This indicates that Comparative Solution is unstable.

10 [0021]

(Example 2) 10.1g of taurine, 179.2g of 50% sodium lactate solution, 107.6g of sodium chloride, and 1.02g of magnesium chloride hexahydrate were dissolved in 10L of water for injection, followed by the addition of sodium hydroxide to adjust the pH of the solution to 7.6. Meanwhile, 272g of glucose and 5.14g of calcium chloride dihydrate were dissolved in 10L of water for injection. Hydrochloric acid was then added to adjust the pH of the solution to 4.2. 750mL of each solution was placed in each compartment of a two-compartment polypropylene bag. After the bag was autoclaved, the solutions were mixed with each other to form Test Solution 4. Similarly, two solutions, having the same composition as Test Solution 4 but containing 15.2g and 20.2g of taurine, respectively, were prepared and were designated as Test Solutions 5 and 6, respectively. Also, a taurine-free solution was prepared to serve as a Comparative Solution. Each solution was observed

after the mixing and after being stored for 10 days at 40°C at 75%RH and was examined for any changes. The results are shown in Table 2 below.

【0022】

5

【Table 2】

Sample	Examined properties	After mixing	10 days later
Test Sltn 4	Appearance	Clear and colorless	Clear and colorless
	PH	7.33	7.14
Test Sltn 5	Appearance	Clear and colorless	Clear and colorless
	PH	7.40	7.19
Test Sltn 6	Appearance	Clear and colorless	Clear and colorless
	PH	7.40	7.22
Comp. Sltn	Appearance	Clear and colorless	Clear and colorless
	PH	7.27	6.83

【0023】

As can be seen from the results, no significant change was observed in the appearance and pH in any of Test Solutions 4, 5, and 6 as compared to Comparative Solution, indicating the stability of each Test Solution.

10

【0024】

(Example 3) Comparative Solution G1 was prepared that contained

5.38g of sodium chloride, 0.257g of calcium chloride dihydrate,
0.0508g of magnesium chloride hexahydrate, 8.96g of 50% sodium
lactate solution, and 13.6g of glucose per 1L. The solution
was sterilized in a two-compartment container and was adjusted
5 so that the pH of the solution upon use would be 7. Similarly,
two solutions, having the same composition as Comparative
Solution G1 but containing 22.7g and 38.6g of glucose,
respectively, were prepared and were designated as Comparative
Solutions G2 and G3, respectively. 30mL of each solution was
10 injected into the abdominal cavity of male SD rats. After 4
hours, the volume of abdominal fluid was measured and the
difference between the volumes of the abdominal fluid and the
administered solution was taken to give the volume of removed
water. The results are shown in Table 3 below.

15

【0025】

【Table 3】

Sample	Conc. of taurine or glucose (w/v%)	Average volume of removed water (mL)	Minimum volume of removed water (mL)	Maximum volume of removed water (mL)
Taurine-containing test solutions				
Test Sltn T1	1.0	0.2	-1.4	1.2
Test Sltn T2	1.8	8.2	6.6	9.5
Test Sltn T3	2.8	13.3	12.3	14.5
Glucose-containing controls				
Comp. Sltn G1	1.36	3.9	1.2	6.0
Comp. Sltn G2	2.27	11.2	10.3	13.0
Comp. Sltn G3	3.86	18.2	16.5	21.3

【0026】

These results indicate that, through the use of taurine, water was removed in a concentration-dependent manner as in the case of the conventional glucose formulation.

【0027】

【Effect of the present invention】

As set forth, the neutral peritoneal dialysate of the present invention, which contains a taurine compound as an osmotic agent, does not bring about the problem of coloring of the dialysate due to decomposition of glucose or the problem of degraded products of glucose. Also, the peritoneal dialysate of the present invention is stable and can be provided

in the form of a single solution in one-compartment containers.
Because the taurine-containing peritoneal dialysate of the
present invention exhibits a good biocompatibility, blood sugar
level can be controlled on diabetic patient and it does not cause
5 the degeneration of the peritoneum mesothelial cell.

Patent Application Number 2002-192177

Approval and Addition Information

Patent Application # Patent Application # 2002-192177
Reference Number 50200961869
5 Name of Document Application for Patent
Responsible Officer TAMARU, Mikio 9079
Date Heisei 14 August 21

<Approval Information and Addition Information >

10 [Date of Submission] Heisei 14 July 1
 [Applicant for the Patent]
 [Identification No.] 392004048
 [Address] 4-24-7, Hongo, Bunkyo-ku, Tokyo
 [Name] SANAKA, Tsutomu
15 [Applicant for the Patent] Applicant
 [Identification No.] 391030963
 [Name] 235, Miyakami, Shimizu-shi,
 Shizuoka
 [Name] Shimizu Pharmaceutical Co.,Ltd.
20 [Applicant for the Patent]
 [Identification No.] 500071175
 [Name] 1-16, Kaigan 2-chome,Minato-ku,
 Tokyo
 [Name] Shimizu Medical Co.,Ltd.

25

Patent Application Number 2002-192177

[Name of Document] Request for Recordation of Change of
Applicant

[Addresses] To Commissioner of the Patent Office

[Identification of the Patent]

5 [Application No.] 2002-192177

[Assignee]

[Equity] 001/002

[Identification No.] 392004048

[Name] SANAKA, Tsutomu

10 [Assignee]

[Equity] 001/002

[Identification No.] 391030963

[Name] Shimizu Pharmaceutical Co., Ltd.

[Representative] YUKAWA, Toshihide

15 [Assignor]

[Identification No.] 500071175

[Name] Shimizu Medical Co., Ltd.

[Representative] YUKAWA, Toshihide

[Charge]

20 [Account Number] 035839

[Total Amount] ¥4,200

[Proof] requested

Patent Application Number 2002-192177

Approval and Addition Information

Patent Application # Patent Application # 2002-192177
Reference Number 50300785991
5 Name of Document Application for Patent
Responsible Officer TAMARU, Mikio 9079
Date Heisei 15 September 12

<Approval Information and Addition Information >

10 [Date of Submission] Heisei 15 May 13
 [Assignee]
 [Identification No.] 392004048
 [Address] 4-24-7, Hongo, Bunkyo-ku, Tokyo
 [Name] SANAHA, Tsutomu
15 [Assignee]
 [Identification No.] 391030963
 [address] 235, Shimizu-Miyakami,
 Shizuoka-shi, Shizuoka
 [Name] Shimizu Pharmaceutical Co.,Ltd.
20 [Assignor]
 [Identification No.] 500071175
 [Name] 1-16, Kaigan 2-chome,Minato-ku,
 Tokyo
 [Name] Shimizu Medical Co.,Ltd.

25

Patent Application Number 2002-192177

[Name of Document] Amendment
[Filing Date] July 22, Heisei 15
[Addresses] To Commissioner of the Patent Office
[Identification of the Patent]

5 [Application No.] 2002-192177

[Person requesting the amendment]

 [Identification No.] 391030963

 [Name] Shimizu Pharmaceutical Co., Ltd.

 [Representative] YUKAWA, Toshihide

10 [Mailing No.] 067724

[Amendment 1]

 [Document to be amended] Request for Recordation
 of Change of Applicant

 [Item to be amended] List of Documents
15 submitted

 [Means of amendment] Addition

 [Amendment]

 [List of documents submitted]

 [Name of the item] Assignment 1

20

[Amendment 2]

[Document to be amended] Request for Recordation
of Change of Applicant

[Item to be amended] Assignee

5 [Means of amendment] Change

[Amendment]

[Assignee]

[Identification No.] 392004048

[Name] SANAKA, Tsutomu

10 [Assignee]

[Identification No.] 391030963

[Name] Shimizu Pharmaceutical Co., Ltd.

[Representative] YUKAWA, Toshihide

[Proof] requested

15

Information on the applicant's personal history

Identification Number [392004048]

5	1.	Date of Change	January 24, 1992
		[Reason for Change]	New Registration
		Address	4-24-7, Hongo, Bunkyo-ku, Tokyo
		Name	SANAKA, Tsutomu

10

Information on the applicant's personal history

Identification Number [391030963]

5 1. Date of Change March 29, 1991
[Reason for Change] New Registration
Address 235, Miyakami, Shimizu-shi, Shizuoka
Name Shimizu Pharmaceutical Co.,Ltd.

10 2. Date of Change April 1, 2003
[Reason for Change] Change of address
Address 235, Shimizu-Miyakami, Shizuoka-shi,
Shizuoka
Name Shimizu Pharmaceutical Co.,Ltd.

15

Patent Application Number 2002-192177

Information on the applicant's personal history

Identification Number [500071175]

5	1.	Date of Change	June 21, 2000
		[Reason for Change]	New Registration
		Address	1-16, Kaigan 2-chome, Minato-ku, Tokyo
		Name	Shimizu Medical Co.,Ltd.

【Name of the Document】 DESCRIPTION
【Name of the Invention】 PERITONEAL DIALYSATE
【Claims】

5 【Claim 1】 A peritoneal dialysate containing a taurine compound along with an electrolyte and an alkalizer.

 【Claim 2】 The peritoneal dialysate according to claim 1, wherein the alkalizer is a lactate, a citrate, or a bicarbonate, and the electrolyte is sodium ion, calcium ion, magnesium ion, or chloride ion.

10 【Claim 3】 The peritoneal dialysate according to claims 1 or 2, having an osmotic pressure of 300 to 680 mOsm.

 【Claim 4】 The peritoneal dialysate according to any one of claims 1 to 3, wherein the pH upon use is adjusted to a value of 6.0 to 7.5.

15 【Claim 5】 The peritoneal dialysate according to any one of claims 1 to 4, provided in a one-compartment container.

 【Claim 6】 A peritoneal dialysate, containing 0.01 to 5 w/v% of taurine, 25 to 45 mEq/L of sodium lactate, 110 to 150 mEq/L of sodium ion, 0.5 to 5 mEq/L of calcium ion, 0.1 to 2.0
20 mEq/L of magnesium ion, 80 to 110 mEq/L of chloride ion, and 0 to 4 w/v% of glucose and having a pH of 6.0 to 7.5 upon use.

 【Claim 7】 A peritoneal dialysate, containing 1 to 5 w/v% of taurine, 25 to 45 mEq/L of sodium lactate, 110 to 150 mEq/L of sodium ion, 0.5 to 5 mEq/L of calcium ion, 0.1 to 2.0
25 mEq/L of magnesium ion, and 80 to 110 mEq/L of chloride ion and having a pH of 6.0 to 7.5.

【Name of the Document】 ABSTRACT

【Abstract】

【Purpose】 It is an objective of the present invention to provide a stable neutral peritoneal dialysate that contains a substance other than glucose to serve as an osmotic agent.

5

【Means to solve the problem】 The peritoneal dialysate of the present invention is stable and can be provided in the form of a single solution in one-compartment containers.